Search
for

    Sort by

    Research 571–600 of 1000+

    1. Diffused alopecia followed by severe acute respiratory syndrome coronavirus-2 infection Libyan journal of medical sciences · 2021
    2. Immunologic and Autoimmune-Related Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Physical Medicine and Rehabilitation Clinics of North America · 2023 · 16 citations
    3. The effect of low-level laser therapy on severe acute respiratory syndrome coronavirus-2 infected cells 2024
    4. Growth hormone deficiency with late-onset hypothalamic hypoadrenocorticism associated with respiratory and renal dysfunction: a case report BMC endocrine disorders · 2020
    5. Symptoms Compatible With Long Coronavirus Disease (COVID) in Healthcare Workers With and Without Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection—Results of a Prospective Multicenter Cohort Clinical Infectious Diseases · 2022 · 35 citations
    6. Late unexpected consequences of COVID‐19 infection in survivors of acute hypoxic respiratory failure Internal Medicine Journal · 2021 · 1 citations
    7. Finasteride Induces Epigenetic Alteration of TMPRss2 Gene Expression: A Potential role in Severe Acute Respiratory Syndrome-Corona Virus-2 Inhibition 2023
    8. Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Frontiers in Medicine · 2020 · 36 citations
    9. Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS‐CoV‐2 in the respiratory tract Pharmacology Research & Perspectives · 2020 · 15 citations
    10. Mitochondrial dysfunction as a cause of ageing Journal of Internal Medicine · 2008 · 384 citations
    11. COVID ‐19 induced telogen effluvium Dermatologic Therapy · 2021 · 22 citations
    12. Aggressive squamous cell carcinoma developing in a giant epidermal cyst of the abdomen International Journal of Dermatology · 2006 · 16 citations
    13. Lupus erythematosus-like lesions in a carrier of X-linked chronic granulomatous disease: A case report and personal considerations International Journal of Dermatology · 2004 · 12 citations
    14. Effects of 5‐alpha reductase inhibitors on lung function: A reason for discontinuation duringCOVID‐19 pandemic? Dermatologic Therapy · 2020 · 5 citations
    15. A MINOR RESEARCH PROJECT ENTITLED-" TO MEASURE THE PRESENCE OF VARIOUS SECONDARY METABOLITIES IN BASIL OIL 2026
    16. MULTIPLE HEMANGIOMAS OF THE TONGUE AND ORAL CAVITY IN A MYOTONIC DYSTROPHY TYPE 1 PATIENT: A CASE REPORT Chest · 2023
    17. BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience British Journal of Dermatology · 2023
    18. 1433 Epithelially derived, mitochondrial MPZL3 negatively regulates murine and human hair follicle cycling Journal of Investigative Dermatology · 2023
    19. Chemical Danger in Hair Keratin Care 2023
    20. Stem Cells Sheltered from Air-Raids Repair Airways Cell stem cell · 2018
    21. Viewpoint 3 Experimental dermatology · 2008
    22. SARS in Children 2005
    23. Health hazard evaluation report: HETA-2000-0176-2829, The Centre for Well-Being at The Phoenician Resort, Scottsdale, Arizona. 2001
    24. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients Journal of The American Academy of Dermatology · 2016 · 238 citations
    25. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta‐analysis Journal of the European Academy of Dermatology and Venereology · 2019 · 54 citations
    26. Tofacitinib therapy for children with severe alopecia areata Journal of the American Academy of Dermatology · 2019 · 39 citations
    27. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials 2022 · 25 citations
    28. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2) American Journal of Clinical Dermatology · 2023 · 20 citations
    29. Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients Dermatologic Therapy · 2019 · 17 citations
    30. Response of alopecia areata of the beard to oral tofacitinib Journal of the American Academy of Dermatology · 2019 · 11 citations